All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Janus kinase 2 (JAK2) is a central kinase in hematopoietic stem cells. Disruption to JAK2 can lead to uncontrolled proliferation of marrow cells, causing AML. JAK2 inhibitors, such as pacritinib and ruxolitinib, are being investigated for the treatment of AML.